Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 Net Margin % is 19.88% as of Mar. 2026, which is 27% above its 10-year median of 15.62. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 960 Drug Manufacturers companies, Jacobson Pharma ranks better than 86.15% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Jacobson Pharma's Net Income for the
six
months ended in Mar. 2026 was HK$160 Mil. Jacobson Pharma's Revenue for the
six
months ended in Mar. 2026 was HK$803 Mil. Therefore, Jacobson Pharma's net margin for the quarter that ended in Mar. 2026 was 19.88%.
The historical rank and industry rank for Jacobson Pharma's Net Margin % or its related term are showing as below:
HKSE:02633'
s Net Margin % Range Over the Past 10 Years
Min: 11.14 Med: 15.62 Max: 19.8
Current: 19.22
HKSE:02633's Net Margin % is ranked better than 86.15% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.205
vs HKSE:02633: 19.22
Jacobson Pharma (HKSE:02633) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jacobson Pharma Net Margin % Related Terms
Jacobson Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a Net Margin % of 19.88% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jacobson Pharma and its competitors. This is 27% above median its historical median of 15.62. Over the past decade, Jacobson Pharma's Net Margin % has ranged from 11.14 to 19.80. According to the industry distribution chart, Jacobson Pharma ranks #133 out of 960 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Jacobson Pharma's Net Margin % too high?
Jacobson Pharma's current Net Margin % of 19.88% is 27% above median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 11.14 to a high of 19.80. The Drug Manufacturers industry median Net Margin % is 5.21. Jacobson Pharma's value of 19.88% is 281.9% above this industry median. Based on the distribution chart, Jacobson Pharma ranks #133 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #133 out of 960 companies for Net Margin %. This places Jacobson Pharma in the top 14% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.21. Jacobson Pharma's value of 19.88% is 281.9% above this benchmark. Historically, Jacobson Pharma's own Net Margin % has ranged from 11.14 to 19.80 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 5.21, Jacobson Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.21, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current Net Margin % of 19.88% is 281.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current Net Margin % is 19.88%, which is 27% above median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Net Margin % is 19.88%, which is 27% above median its 10-year median of 15.62 and 281.9% above the Drug Manufacturers industry median of 5.21. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Net Margin % is 19.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
Net Margin %: 19.88% (27% above median its 10-year median of 15.62)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 281.9% above the Drug Manufacturers median (#133 of 960)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
